Pain Management Drugs Market Report 2026

The pain management drugs market size has grown strongly in recent years. It will grow from $84.79 billion in 2025 to $89.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to rising prevalence of chronic pain conditions, increasing geriatric population, growing awareness about pain management, expansion of hospital and retail pharmacy networks, advancements in analgesic drug formulations.

The pain management drugs market size is expected to see strong growth in the next few years. It will grow to $108.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rising adoption of biologics for pain management, increasing integration of digital health solutions, growing demand for minimally invasive procedures, expansion of home healthcare services, innovation in combination therapies. Major trends in the forecast period include personalized pain management therapies, telemedicine & remote pain monitoring, novel analgesic drug formulations, minimally invasive pain relief techniques, combination therapy approaches.

The increasing geriatric population is expected to drive the growth of the pain management drugs market in the future. The geriatric population, defined as individuals aged 65 and older, often requires pain management medications to alleviate conditions like arthritis, cancer, neurological disorders, and other age-related ailments. As such, the rising number of elderly individuals is expected to boost the demand for pain management drugs. For example, in November 2025, the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental economic organization, reported that, over the past 50 years, the share of the population aged 65 and older has doubled on average across OECD countries, increasing from 18.5% in 2023. Consequently, the growth of the geriatric population is a key factor driving the expansion of the pain management drugs market.

Leading companies in the pain management drugs market are focused on developing new drugs and obtaining FDA approval to meet the needs of patients dealing with acute or chronic pain. FDA approval is the regulatory endorsement granted by the U.S. Food and Drug Administration, indicating that a medical product meets the necessary safety and efficacy standards for distribution in the U.S. For instance, in October 2023, Hyloris Pharmaceuticals, a Belgium-based pharmaceutical company, received U.S. FDA approval for Maxigesic IV. Maxigesic IV is the first non-opioid painkiller approved by the FDA in over 20 years. This non-opioid intravenous painkiller combines paracetamol and ibuprofen to provide a dual-action mechanism for pain relief. The approval of Maxigesic IV marks a significant milestone in the pain management drugs market, offering a new non-opioid option for post-operative pain relief.

In May 2025, Eli Lilly, a U.S.-based pharmaceutical company specializing in multiple therapeutic areas, including oncology, diabetes, and immunology, acquired SiteOne Therapeutics for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its pain management portfolio by advancing non-opioid, innovative therapies for chronic pain. SiteOne Therapeutics, a U.S.-based biotechnology company, is developing novel non-opioid pain treatments, including STC 004, a sodium-channel inhibitor for chronic pain.

Major companies operating in the pain management drugs market are Novartis AG, Eli Lilly And Company, Abbott Laboratories, Endo International plc, Pfizer Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., GlaxoSmithKline plc, AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bausch Health Companies Inc., Sanofi, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, Mallinckrodt Pharmaceuticals, Daiichi Sankyo Company Limited, Grünenthal GmbH, Mundipharma International Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Zydus Cadila, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd.

North America was the largest region in the pain management drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the pain management drug market report during the forecast period. The regions covered in the pain management drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pain management drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pain management drugs market by affecting the cost and availability of imported active pharmaceutical ingredients (APIs) and specialized drug formulations. The resulting price fluctuations impact hospital pharmacies and retail distribution channels, particularly in North America and Europe. Segments such as opioids and biologics are most affected due to high import dependency. Positive impacts include encouraging local manufacturing, boosting domestic production capabilities, and driving innovation in cost-effective pain management solutions.

The pain management drugs market research report is one of a series of new reports that provides pain management drugs market statistics, including pain management drugs industry global market size, regional shares, competitors with a pain management drugs market share, detailed pain management drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pain management drugs industry. This pain management drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A pain management drug is a medication that alleviates pain. These drugs work by producing analgesia through various actions in the nervous system, such as inhibiting neurotransmitter release from primary afferent terminals in the spinal cord and activating descending inhibitory controls in the midbrain.

The primary classes of pain management drugs include non-steroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. NSAIDs are a type of nonsteroidal anti-inflammatory drug used to reduce high fever, decrease inflammation, and relieve discomfort. These drugs are indicated for a range of conditions, including arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraines, fibromyalgia, muscle sprains/strains, bone fractures, and more. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The pain management drug market consists of sales of acetaminophen, anti-seizure medications, steroids, muscle relaxers, and other related drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.